Suzhou Xikero Pharmaceutical

Suzhou Xikero Pharmaceutical is a China-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics for challenging "undruggable" targets. The company leverages a proprietary platform that integrates fragment-based drug discovery (FBDD), structure-based drug design (SBDD), and advanced biophysical screening techniques. Xikero's research primarily targets protein-protein interactions (PPIs) which are critical in the progression of cancer and immunological diseases. Its lead pipeline candidate, XKR-001, is a potent small molecule inhibitor targeting the KRAS G12D mutation for the treatment of solid tumors. Founded in 2018 and headquartered in the Suzhou Industrial Park, the company is backed by prominent venture capital firms including Oriza Holdings and Northern Light Venture Capital. Xikero aims to address significant unmet medical needs by delivering first-in-class medicines to patients globally through its specialized expertise in structural biology and medicinal chemistry.